Kathleen S Wilson, MD | |
6000 Harry Hines Blvd, Hamon Bldg, Room Na2 508a, Dallas, TX 75390-0001 | |
(214) 648-1620 | |
(214) 648-4080 |
Full Name | Kathleen S Wilson |
---|---|
Gender | Female |
Speciality | Pathology |
Experience | 33 Years |
Location | 6000 Harry Hines Blvd, Dallas, Texas |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1184711582 | NPI | - | NPPES |
110712003 | Medicaid | TX |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207ZP0007X | Pathology - Molecular Genetic Pathology | J2416 (Texas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Ut Southwestern University Hospital - William P. Clements Jr. | Dallas, TX | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Of Texas Southwestern Medical Center | 0648188250 | 2588 |
News Archive
New regulations which will better protect the rights, safety and well-being of patients taking part in clinical trials of medicines were welcomed today by Health Minister, Lord Warner.
Research published in the Cancer Cell journal in March was a significant step in knowing the causes of cancer better, especially breast cancer, revealing that the lack or loss of a protein in the cells known as SIRT3, induces the proliferation of this disease and thereby, this protein can be an may be a therapeutic target in the development of effective therapies for cancer. The research was led by Dra. Marcia Haigis of the Harvard Medical School, with the participation of Dr. Arkaitz Carracedo, from the Proteomics Laboratory at CIC bioGUNE.
Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, today announced the completion of a $25 million Series C round of growth capital financing. New investor ProQuest Investments led the round, joined by all current investors: Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.
Eli Lilly and Company and Sarah Cannon Research Institute today announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.
› Verified 4 days ago
Entity Name | University Of Texas Southwestern Medical Center At Dallas |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1972579365 PECOS PAC ID: 0648188250 Enrollment ID: O20031106000792 |
News Archive
New regulations which will better protect the rights, safety and well-being of patients taking part in clinical trials of medicines were welcomed today by Health Minister, Lord Warner.
Research published in the Cancer Cell journal in March was a significant step in knowing the causes of cancer better, especially breast cancer, revealing that the lack or loss of a protein in the cells known as SIRT3, induces the proliferation of this disease and thereby, this protein can be an may be a therapeutic target in the development of effective therapies for cancer. The research was led by Dra. Marcia Haigis of the Harvard Medical School, with the participation of Dr. Arkaitz Carracedo, from the Proteomics Laboratory at CIC bioGUNE.
Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, today announced the completion of a $25 million Series C round of growth capital financing. New investor ProQuest Investments led the round, joined by all current investors: Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.
Eli Lilly and Company and Sarah Cannon Research Institute today announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Kathleen S Wilson, MD Po Box 845347, Dallas, TX 75284-5347 Ph: (214) 648-1620 | Kathleen S Wilson, MD 6000 Harry Hines Blvd, Hamon Bldg, Room Na2 508a, Dallas, TX 75390-0001 Ph: (214) 648-1620 |
News Archive
New regulations which will better protect the rights, safety and well-being of patients taking part in clinical trials of medicines were welcomed today by Health Minister, Lord Warner.
Research published in the Cancer Cell journal in March was a significant step in knowing the causes of cancer better, especially breast cancer, revealing that the lack or loss of a protein in the cells known as SIRT3, induces the proliferation of this disease and thereby, this protein can be an may be a therapeutic target in the development of effective therapies for cancer. The research was led by Dra. Marcia Haigis of the Harvard Medical School, with the participation of Dr. Arkaitz Carracedo, from the Proteomics Laboratory at CIC bioGUNE.
Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, today announced the completion of a $25 million Series C round of growth capital financing. New investor ProQuest Investments led the round, joined by all current investors: Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.
Eli Lilly and Company and Sarah Cannon Research Institute today announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.
› Verified 4 days ago
Dr. Jaime Albert Campbell, M.D., M.S. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3500 Gaston Ave, Baylor University Medical Center, Dept Of Pathology, Dallas, TX 75246 Phone: 214-820-3772 | |
Brianne Flynn, Pathology Medicare: Not Enrolled in Medicare Practice Location: 2355 N Stemmons Fwy, Dallas, TX 75207 Phone: 214-920-5900 | |
Dr. Timothy Joseph Kirtek, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd Stop 7200, Dallas, TX 75390 Phone: 214-648-3433 | |
Keith Allen Wharton Jr., MD PHD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-1620 Fax: 214-648-4080 | |
Dinesh Rakheja, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-1620 Fax: 214-648-4080 | |
Dr. Emmy L. Kiss, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-590-6494 | |
Thomas Hugh Mcconnell, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 3401 Lee Pkwy Apt 304, Dallas, TX 75219 Phone: 214-363-2221 Fax: 214-363-2228 |